"I Can't Just Watch My Children Die"

The Father Who Built a Pharmaceutical Company to Save His Kids: The John Crowley Story

A Death Sentence for Two Children

In 1998, John Crowley was a young father in his early thirties living in New Jersey. A Harvard Business School graduate working in management consulting, he and his wife Aileen were raising three children in what seemed like a perfectly ordinary American household.

Then their world collapsed.

Their second child, Megan, was diagnosed at fifteen months old with Pompe disease — an extremely rare genetic disorder in which the body lacks a critical enzyme called acid alpha-glucosidase (GAA). Without this enzyme, glycogen accumulates in the muscles, progressively destroying them. The heart enlarges. Breathing becomes impossible. For infants with the most severe form, the prognosis was devastating: most patients did not survive past their second birthday.

Shortly after Megan's diagnosis, their youngest son Patrick received the same verdict.

There was no treatment. There was no cure. There was, doctors told the Crowleys gently, no hope.

An Impossible Decision

John Crowley was not a doctor. He was not a scientist. He was a businessman who had never taken a single biochemistry course. But he was a father watching two of his children slowly suffocate as their muscles weakened and their hearts struggled to beat.

He refused to accept the prognosis.

Night after night, after putting the children to bed and listening to the rhythmic hiss of Megan's ventilator, Crowley began reading medical journals. He taught himself the biology of lysosomal storage disorders. He tracked down every researcher in the world who had ever published a paper on Pompe disease.

His search led him to Dr. William Canfield at the University of Oklahoma and Dr. Yuan-Tsong Chen at Duke University, scientists who were exploring a promising but underfunded approach: Enzyme Replacement Therapy (ERT) — the idea that if you could manufacture the missing enzyme and infuse it into the patient's body, you might halt the disease's relentless destruction.

The science was promising. The funding was nonexistent.

So John Crowley did something that stunned everyone who knew him. In 2000, he quit his stable, well-paying job and founded Novazyme Pharmaceuticals, a biotech startup dedicated to developing a Pompe disease treatment.

He had no medical credentials. He had no pharmaceutical experience. He had two dying children and an unshakable conviction that he could not stand by and do nothing.

Racing Against Time

The clock was merciless. Megan was already dependent on a ventilator. Patrick was losing mobility. Every week that passed without a treatment meant more irreversible muscle damage.

Crowley threw himself into the work with a ferocity that awed and sometimes alarmed his colleagues. He flew across the country to pitch investors, most of whom politely declined. He recruited scientists, negotiated licensing agreements, and pored over research data late into the night.

Novazyme made progress, but a small startup could not carry a drug through the enormously expensive process of clinical trials and FDA approval alone. In 2001, Crowley made the most painful business decision of his life: he sold Novazyme to Genzyme Corporation, one of the world's leading biotechnology companies, in a deal worth approximately $137.5 million.

He surrendered control of the company he had built. He did it without hesitation. The only thing that mattered was getting the drug to his children.

Crowley joined Genzyme as Senior Vice President of its Pompe disease program, driving the development effort from within. But this created a profound ethical dilemma: could a pharmaceutical executive's own children be enrolled in the clinical trial he was overseeing? The potential conflict of interest was obvious.

Crowley handled it with transparency. An independent ethics committee reviewed the situation. He stepped back from any decisions involving patient selection. The process was scrutinized and ultimately approved.

The Miracle

In 2003, Megan and Patrick Crowley began receiving the experimental enzyme replacement therapy. Megan was six years old. Patrick was four. Both had already far outlived the life expectancy doctors had given them — a testament to the extraordinary care their parents had provided and, perhaps, to sheer stubborn love.

The results were remarkable. The children's enlarged hearts began to shrink toward normal size. The progressive muscle deterioration stabilized. They were not cured — the damage already done to their muscles could not be fully reversed — but the disease stopped advancing.

On April 28, 2006, the U.S. Food and Drug Administration approved Myozyme (alglucosidase alfa) as the first-ever treatment for Pompe disease. It was a landmark moment in the history of rare disease medicine.

John Crowley's children were alive. And they would stay alive.

Beyond the Family

Megan Crowley graduated from high school in a wheelchair, breathing with the help of a ventilator, but intellectually sharp and fiercely determined. She went on to attend the University of Notre Dame, where she became an advocate for disability rights and rare disease research. Patrick also attended college and has continued to thrive.

Both are now in their mid-twenties — more than two decades past the death sentence they received as infants.

The Crowley family's story was adapted into the 2010 film "Extraordinary Measures," starring Brendan Fraser as John Crowley and Harrison Ford as a composite character based on the scientists who helped develop the therapy.

But the impact extends far beyond one family. Myozyme — and its next-generation successor, Lumizyme — is now administered to thousands of Pompe disease patients worldwide. Children who once had no chance of survival are growing up, going to school, living lives that would have been impossible a generation ago.

John Crowley went on to serve as CEO of Amicus Therapeutics, continuing his mission to develop treatments for rare diseases. He has become one of the most prominent patient-advocates in the pharmaceutical industry, a living example of what happens when love refuses to accept the impossible.

A Father's Words

In countless interviews over the years, Crowley has deflected the word "hero." His answer is always the same:

"I'm not a scientist. I'm not a hero. I'm just a dad. Any parent would have done what I did. When your children are dying and you have even the slightest chance of saving them, you don't think about it. You just move."

What makes John Crowley's story extraordinary is not just that he saved his own children. It is that in doing so, he changed the world for every family that would ever hear the words "Pompe disease." He transformed a death sentence into a treatable condition. He proved that a single person, driven by love, can bend the arc of medical science.

His story reminds us of a simple, staggering truth: a parent's love is the most powerful force on earth. It can build companies, move bureaucracies, rewrite textbooks, and — against every odd — keep a child's heart beating.

"To every mother and father out there — never stop fighting for your child." — John Crowley

"I Can't Just Watch My Children Die" — The Father Who Built a Pharmaceutical Company to Save His Kids: The John Crowley Story